Assembly Biosciences (ASMB)
Assembly Biosciences on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
2.9M
Short interest
settlement 2026-10-15
11.1
Days to cover
+4.2 days vs prior
69.5%
Short share of volume
2026-11-02
2,727
Fails to deliver
settlement 2026-08-31
Mon 9 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ASMB is 2,913,451 shares, up 817,883 shares over the last month. Over the last 48 readings it ranged from 7,949 shares (31 October 2024) to 2,913,451 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 263K shares a day that is 11.1 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/asmb" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 2,913,451 | +3.2% | 263,103 | 11.07 |
| 2026-09-30 | 2,822,392 | +34.7% | 412,950 | 6.83 |
| 2026-09-15 | 2,095,568 | -1.2% | 334,747 | 6.26 |
| 2026-08-31 | 2,120,055 | -8.4% | 314,272 | 6.75 |
| 2026-08-14 | 2,314,029 | -0.9% | 230,357 | 10.05 |
| 2026-07-31 | 2,335,806 | +1.0% | 147,661 | 15.82 |
| 2026-07-15 | 2,312,058 | -4.0% | 157,302 | 14.70 |
| 2026-06-30 | 2,407,951 | +29.1% | 365,563 | 6.59 |
| 2026-06-15 | 1,865,461 | +10.8% | 198,285 | 9.41 |
| 2026-05-29 | 1,683,891 | +9.1% | 223,737 | 7.53 |
| 2026-05-15 | 1,543,140 | -0.9% | 163,858 | 9.42 |
| 2026-04-30 | 1,557,158 | +1.7% | 100,559 | 15.49 |
| 2026-04-15 | 1,530,956 | -0.1% | 93,282 | 16.41 |
| 2026-03-31 | 1,533,102 | +0.8% | 68,428 | 22.40 |
| 2026-03-13 | 1,520,887 | +2.8% | 82,191 | 18.50 |
| 2026-02-27 | 1,479,082 | -0.4% | 125,632 | 11.77 |
| 2026-02-13 | 1,485,390 | -3.4% | 86,135 | 17.24 |
| 2026-01-30 | 1,537,870 | -1.7% | 109,929 | 13.99 |
| 2026-01-15 | 1,565,129 | +1.4% | 102,473 | 15.27 |
| 2025-12-31 | 1,543,026 | +13.0% | 179,355 | 8.60 |
| 2025-12-15 | 1,365,795 | +5.9% | 101,555 | 13.45 |
| 2025-11-28 | 1,289,499 | -1.3% | 127,765 | 10.09 |
| 2025-11-14 | 1,306,741 | +1.3% | 140,235 | 9.32 |
| 2025-10-31 | 1,289,657 | -15.9% | 123,713 | 10.42 |
| 2025-10-15 | 1,534,291 | +13.5% | 144,268 | 10.64 |
| 2025-09-30 | 1,352,256 | +26.8% | 190,445 | 7.10 |
| 2025-09-15 | 1,066,154 | +17.0% | 137,662 | 7.74 |
| 2025-08-29 | 911,201 | +71.6% | 151,876 | 6.00 |
| 2025-08-15 | 530,934 | +1699.1% | 145,774 | 3.64 |
| 2025-07-31 | 29,511 | -3.7% | 24,672 | 1.20 |
| 2025-07-15 | 30,649 | +0.1% | 35,184 | 1.00 |
| 2025-06-30 | 30,615 | +84.7% | 49,511 | 1.00 |
| 2025-06-13 | 16,578 | +19.3% | 25,287 | 1.00 |
| 2025-05-30 | 13,895 | -47.2% | 12,481 | 1.11 |
| 2025-05-15 | 26,314 | +99.2% | 22,801 | 1.15 |
| 2025-04-30 | 13,209 | -29.0% | 11,701 | 1.13 |
| 2025-04-15 | 18,615 | +8.6% | 39,785 | 1.00 |
| 2025-03-31 | 17,139 | -17.2% | 34,062 | 1.00 |
| 2025-03-14 | 20,705 | +1.9% | 20,249 | 1.02 |
| 2025-02-28 | 20,313 | +17.9% | 31,032 | 1.00 |
| 2025-02-14 | 17,226 | +25.5% | 23,044 | 1.00 |
| 2025-01-31 | 13,724 | -4.8% | 19,785 | 1.00 |
| 2025-01-15 | 14,424 | +9.6% | 34,054 | 1.00 |
| 2024-12-31 | 13,161 | -1.2% | 47,810 | 1.00 |
| 2024-12-13 | 13,318 | -16.1% | 31,265 | 1.00 |
| 2024-11-29 | 15,883 | +37.6% | 38,004 | 1.00 |
| 2024-11-15 | 11,545 | +45.2% | 25,059 | 1.00 |
| 2024-10-31 | 7,949 | -51.6% | 24,956 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ASMB volume is 69.5%, up 7.3 points over the last five sessions. Over the last 30 readings it ranged from 21.5% (22 September 2026) to 76.8% (8 October 2026). The latest reading is 12.9 points above the 30-session average of 56.6%, on 83K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 58K | 83K | 69.5% | 2,955 |
| 2026-10-30 | 34K | 46K | 75.0% | 0 |
| 2026-10-29 | 51K | 79K | 64.7% | 0 |
| 2026-10-28 | 30K | 46K | 64.8% | 0 |
| 2026-10-27 | 33K | 59K | 55.7% | 0 |
| 2026-10-26 | 33K | 53K | 62.2% | 0 |
| 2026-10-23 | 46K | 66K | 70.5% | 0 |
| 2026-10-22 | 21K | 40K | 52.1% | 0 |
| 2026-10-21 | 64K | 95K | 66.6% | 0 |
| 2026-10-20 | 49K | 70K | 69.8% | 0 |
| 2026-10-19 | 40K | 60K | 66.8% | 0 |
| 2026-10-16 | 24K | 54K | 43.3% | 0 |
| 2026-10-15 | 36K | 74K | 48.0% | 0 |
| 2026-10-14 | 43K | 80K | 54.4% | 615 |
| 2026-10-13 | 32K | 77K | 41.6% | 370 |
| 2026-10-12 | 47K | 104K | 45.2% | 0 |
| 2026-10-09 | 46K | 64K | 71.4% | 0 |
| 2026-10-08 | 37K | 48K | 76.8% | 0 |
| 2026-10-07 | 53K | 70K | 76.4% | 0 |
| 2026-10-06 | 43K | 78K | 55.5% | 0 |
| 2026-10-05 | 51K | 82K | 62.0% | 0 |
| 2026-10-02 | 97K | 149K | 65.2% | 1,800 |
| 2026-10-01 | 75K | 195K | 38.7% | 0 |
| 2026-09-30 | 27K | 77K | 35.1% | 0 |
| 2026-09-29 | 30K | 89K | 34.1% | 0 |
| 2026-09-28 | 20K | 38K | 54.1% | 0 |
| 2026-09-25 | 26K | 47K | 54.8% | 0 |
| 2026-09-24 | 34K | 64K | 52.7% | 0 |
| 2026-09-23 | 46K | 96K | 48.1% | 0 |
| 2026-09-22 | 83K | 387K | 21.5% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 31 August 2026, the fails-to-deliver balance in ASMB is 2,727 shares, down 1,654 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (18 June 2026) to 39,638 shares (30 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-31 | 2,727 | $34.07 | $93K |
| 2026-08-19 | 4,381 | $32.13 | $141K |
| 2026-08-17 | 283 | $32.95 | $9K |
| 2026-08-05 | 51 | $26.44 | $1K |
| 2026-07-27 | 1,780 | $25.55 | $45K |
| 2026-07-16 | 13 | $26.73 | $347 |
| 2026-07-08 | 6 | $28.97 | $174 |
| 2026-07-07 | 4 | $28.90 | $116 |
| 2026-07-01 | 116 | $27.48 | $3K |
| 2026-06-30 | 39,638 | $26.96 | $1.1M |
| 2026-06-29 | 138 | $26.74 | $4K |
| 2026-06-26 | 163 | $24.26 | $4K |
| 2026-06-24 | 1,153 | $26.80 | $31K |
| 2026-06-23 | 903 | $25.15 | $23K |
| 2026-06-22 | 8 | $24.44 | $196 |
| 2026-06-18 | 1 | $24.15 | $24 |
| 2026-06-17 | 5,172 | $23.33 | $121K |
| 2026-06-16 | 1,934 | $23.34 | $45K |
| 2026-06-15 | 288 | $22.96 | $7K |
| 2026-06-08 | 600 | $22.90 | $14K |
| 2026-06-05 | 600 | $24.11 | $14K |
| 2026-05-13 | 463 | $30.82 | $14K |
| 2026-05-04 | 203 | $27.37 | $6K |
| 2026-04-13 | 3,913 | $28.42 | $111K |
| 2026-04-09 | 2 | $29.35 | $59 |
| 2026-04-08 | 399 | $28.53 | $11K |
| 2026-03-31 | 508 | $26.64 | $14K |
| 2026-03-23 | 309 | $28.46 | $9K |
| 2026-03-04 | 460 | $28.80 | $13K |
| 2026-02-04 | 53 | $28.24 | $1K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for ASMB in the last 90 days. The most recent filings are listed below. Latest filing: Bjorkquist Jeanette M (PFO and PAO) on 2026-06-17.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-06-17 | Bjorkquist Jeanette M | PFO and PAO | Sell | 29 | $23.25 | $674 | 15K |
| 2026-05-26 | GILEAD SCIENCES, INC. | 10% owner | Grant | 472K | $26.50 | $12.5M | 5.0M |
| 2026-03-30 | Bjorkquist Jeanette M | PFO and PAO | Sell | 16 | $27.49 | $440 | 11K |
| 2026-03-30 | Bjorkquist Jeanette M | PFO and PAO | Sell | 312 | $26.65 | $8K | 11K |
| 2026-03-30 | White Nicole S | Chief Manufacturing Officer | Sell | 9 | $27.49 | $247 | 37K |
| 2026-03-30 | White Nicole S | Chief Manufacturing Officer | Sell | 188 | $26.65 | $5K | 37K |
| 2026-03-29 | Bjorkquist Jeanette M | PFO and PAO | Grant | 7K | $0.00 | $0 | 11K |
| 2026-03-29 | White Nicole S | Chief Manufacturing Officer | Grant | 26K | $0.00 | $0 | 38K |
| 2026-03-29 | Gaggar Anuj | Chief Medical Officer | Grant | 26K | $0.00 | $0 | 28K |
| 2026-03-29 | Delaney William E IV | Chief Scientific Officer | Grant | 26K | $0.00 | $0 | 46K |
| 2026-03-29 | Okazaki Jason A | CEO and President | Grant | 94K | $0.00 | $0 | 112K |
| 2026-03-29 | Gaggar Anuj | Chief Medical Officer | Grant | 14K | $0.00 | $0 | 43K |
| 2026-03-29 | White Nicole S | Chief Manufacturing Officer | Grant | 14K | $0.00 | $0 | 48K |
| 2026-03-29 | Bjorkquist Jeanette M | PFO and PAO | Grant | 4K | $0.00 | $0 | 15K |
| 2026-03-29 | Delaney William E IV | Chief Scientific Officer | Grant | 14K | $0.00 | $0 | 60K |
| 2026-03-29 | Okazaki Jason A | CEO and President | Grant | 51K | $0.00 | $0 | 163K |
| 2025-08-08 | GILEAD SCIENCES, INC. | TenPercentOwner | Buy | 2.3M | $19.60 | $45.0M | 4.5M |
| 2025-06-16 | Bjorkquist Jeanette M | PFO and PAO | Grant | 300 | $0.00 | $0 | 5K |
| 2025-03-31 | White Nicole S | Chief Manufacturing Officer | Sell | 197 | $9.85 | $2K | 12K |
| 2025-03-31 | Okazaki Jason A | CEO and President | Sell | 355 | $9.85 | $3K | 15K |
| 2025-03-31 | Bjorkquist Jeanette M | Principal Accounting Officer | Sell | 180 | $9.85 | $2K | 5K |
| 2025-03-31 | McHutchison John G | Director | Sell | 757 | $9.85 | $7K | 18K |
| 2025-03-29 | Bjorkquist Jeanette M | Principal Accounting Officer | Grant | 2K | $0.00 | $0 | 5K |
| 2024-12-30 | Houghton Michael | Director | Buy | 3K | $15.61 | $50K | 3K |
| 2024-12-19 | GILEAD SCIENCES, INC. | TenPercentOwner | Buy | 940K | $21.37 | $20.1M | 2.2M |
| 2024-11-25 | Schornstein Alexander | TenPercentOwner | Buy | 5K | $14.85 | $74K | 728K |
| 2024-11-25 | Schornstein Alexander | TenPercentOwner | Buy | 3K | $15.00 | $45K | 723K |
| 2024-11-22 | Schornstein Alexander | TenPercentOwner | Buy | 17K | $14.87 | $253K | 720K |
| 2024-11-18 | White Nicole S | Chief Manufacturing Officer | Sell | 40 | $16.29 | $652 | 12K |
| 2024-10-08 | Schornstein Alexander | TenPercentOwner | Buy | 10K | $14.58 | $146K | 703K |
| 2024-10-03 | Okazaki Jason A | CEO and President | Sell | 197 | $14.81 | $3K | 15K |
| 2024-10-03 | White Nicole S | Chief Manufacturing Officer | Sell | 157 | $14.81 | $2K | 12K |
| 2024-08-02 | Okazaki Jason A | CEO and President | Sell | 981 | $14.23 | $14K | 15K |
| 2024-08-02 | White Nicole S | Chief Manufacturing Officer | Sell | 785 | $14.23 | $11K | 12K |
| 2024-07-05 | Schornstein Alexander | TenPercentOwner | Buy | 4K | $12.52 | $56K | 693K |
| 2024-07-03 | Schornstein Alexander | TenPercentOwner | Buy | 5K | $12.29 | $56K | 689K |
| 2024-06-17 | GILEAD SCIENCES, INC. | TenPercentOwner | Buy | 180K | $15.46 | $2.8M | 1.3M |
| 2024-05-23 | Okazaki Jason A | CEO and President | Sell | 549 | $14.93 | $8K | 16K |
| 2024-05-23 | White Nicole S | Chief Manufacturing Officer | Sell | 172 | $14.93 | $3K | 13K |
| 2024-05-23 | McHutchison John G | Director | Sell | 2K | $14.93 | $32K | 19K |
| 2024-05-23 | Bjorkquist Jeanette M | Principal Accounting Officer | Sell | 24 | $14.93 | $358 | 3K |
| 2024-04-30 | Okazaki Jason A | CEO and President | Sell | 2K | $12.71 | $20K | 16K |
| 2024-04-30 | White Nicole S | Chief Manufacturing Officer | Sell | 1K | $12.71 | $16K | 13K |
| 2024-04-29 | Delaney William E IV | Chief Scientific Officer | Grant | 3K | $0.00 | $0 | 16K |
| 2024-04-29 | Okazaki Jason A | CEO and President | Grant | 4K | $0.00 | $0 | 18K |
| 2024-04-29 | White Nicole S | Chief Manufacturing Officer | Grant | 3K | $0.00 | $0 | 14K |
| 2024-04-01 | Okazaki Jason A | CEO and President | Sell | 354 | $13.07 | $5K | 14K |
| 2024-04-01 | White Nicole S | Chief Manufacturing Officer | Sell | 197 | $13.07 | $3K | 11K |
| 2024-04-01 | Bjorkquist Jeanette M | Principal Accounting Officer | Sell | 114 | $13.07 | $1K | 3K |
| 2024-04-01 | McHutchison John G | Director | Sell | 1K | $13.07 | $16K | 21K |
| 2024-03-29 | Bjorkquist Jeanette M | Principal Accounting Officer | Grant | 850 | $0.00 | $0 | 3K |
| 2024-03-27 | Okazaki Jason A | CEO and President | Sell | 392 | $12.87 | $5K | 14K |
| 2024-01-18 | Schornstein Alexander | TenPercentOwner | Buy | 345K | $0.80 | $276K | 8.2M |
| 2024-01-17 | Schornstein Alexander | TenPercentOwner | Buy | 300K | $0.78 | $234K | 7.9M |
| 2023-11-21 | Schornstein Alexander | TenPercentOwner | Buy | 100K | $0.67 | $67K | 7.6M |
| 2023-11-20 | Schornstein Alexander | TenPercentOwner | Buy | 300K | $0.72 | $216K | 7.5M |
| 2023-11-17 | White Nicole S | Chief Manufacturing Officer | Sell | 477 | $0.69 | $329 | 94K |
| 2023-10-03 | Okazaki Jason A | CEO and President | Sell | 2K | $0.80 | $2K | 175K |
| 2023-10-03 | Delaney William E IV | Chief Scientific Officer | Sell | 2K | $0.80 | $2K | 151K |
| 2023-10-03 | White Nicole S | Chief Manufacturing Officer | Sell | 2K | $0.80 | $2K | 94K |
| 2023-10-02 | Okazaki Jason A | CEO and President | Grant | 13K | $0.00 | $0 | 177K |
| 2023-10-02 | Delaney William E IV | Chief Scientific Officer | Grant | 10K | $0.00 | $0 | 153K |
| 2023-10-02 | White Nicole S | Chief Manufacturing Officer | Grant | 10K | $0.00 | $0 | 96K |
| 2023-08-02 | Okazaki Jason A | CEO and President | Sell | 12K | $1.09 | $13K | 165K |
| 2023-08-02 | Delaney William E IV | Chief Scientific Officer | Sell | 9K | $1.09 | $10K | 143K |
| 2023-07-24 | Bjorkquist Jeanette M | Principal Accounting Officer | Sell | 844 | $1.07 | $903 | 27K |
| 2023-06-22 | Okazaki Jason A | CEO and President | Grant | 50K | $0.00 | $0 | 177K |
| 2023-06-22 | Delaney William E IV | Chief Scientific Officer | Grant | 40K | $0.00 | $0 | 152K |
| 2023-05-30 | Delaney William E IV | Chief Scientific Officer | Sell | 4K | $0.96 | $4K | 112K |
| 2023-05-23 | Okazaki Jason A | CEO and President | Sell | 7K | $1.04 | $7K | 127K |
| 2023-05-23 | Delaney William E IV | Chief Scientific Officer | Sell | 7K | $1.04 | $7K | 116K |
| 2023-05-23 | Bjorkquist Jeanette M | Principal Accounting Officer | Sell | 274 | $1.04 | $285 | 28K |
| 2023-05-23 | McHutchison John G | Director | Sell | 26K | $1.04 | $27K | 169K |
| 2023-05-22 | Okazaki Jason A | CEO and President | Grant | 35K | $0.00 | $0 | 133K |
| 2023-05-22 | Delaney William E IV | Chief Scientific Officer | Grant | 35K | $0.00 | $0 | 123K |
| 2023-05-22 | Bjorkquist Jeanette M | Principal Accounting Officer | Grant | 2K | $0.00 | $0 | 28K |
| 2023-05-22 | McHutchison John G | Director | Grant | 118K | $0.00 | $0 | 295K |
| 2023-03-30 | Okazaki Jason A | CEO and President | Sell | 4K | $0.82 | $3K | 98K |
| 2023-03-30 | Delaney William E IV | Chief Scientific Officer | Sell | 3K | $0.82 | $3K | 85K |
| 2023-03-30 | Bjorkquist Jeanette M | Principal Accounting Officer | Sell | 774 | $0.82 | $635 | 24K |
| 2023-03-30 | McHutchison John G | Director | Sell | 15K | $0.82 | $12K | 178K |
| 2023-03-29 | Bjorkquist Jeanette M | Principal Accounting Officer | Grant | 6K | $0.00 | $0 | 25K |
| 2023-03-27 | Okazaki Jason A | CEO and President | Sell | 5K | $1.02 | $5K | 102K |
| 2023-02-16 | Okazaki Jason A | CEO and President | Grant | 13K | $0.00 | $0 | 107K |
| 2023-02-16 | Delaney William E IV | Chief Scientific Officer | Grant | 10K | $0.00 | $0 | 89K |
| 2022-08-08 | McHutchison John G | Chief Executive Officer | Sell | 12K | $2.13 | $26K | 193K |
| 2022-07-25 | Samar Michael P. | Chief Financial Officer | Sell | 2K | $2.22 | $4K | 77K |
| 2022-05-31 | Delaney William E IV | Chief Scientific Officer | Sell | 4K | $1.92 | $8K | 76K |
| 2022-03-30 | McHutchison John G | CEO and President | Sell | 5K | $2.17 | $10K | 205K |
| 2022-03-30 | Okazaki Jason A | Chief Operating Officer | Sell | 1K | $2.17 | $3K | 95K |
| 2022-03-30 | Delaney William E IV | Chief Scientific Officer | Sell | 1K | $2.17 | $2K | 78K |
| 2022-03-30 | Stamm Luisa M | Chief Medical Officer | Sell | 1K | $2.17 | $2K | 40K |
| 2022-03-30 | Samar Michael P. | Chief Financial Officer | Sell | 2K | $2.17 | $5K | 77K |
| 2022-03-29 | McHutchison John G | CEO and President | Grant | 84K | $0.00 | $0 | 209K |
| 2022-03-29 | Okazaki Jason A | Chief Operating Officer | Grant | 31K | $0.00 | $0 | 96K |
| 2022-03-29 | Delaney William E IV | Chief Scientific Officer | Grant | 25K | $0.00 | $0 | 79K |
| 2022-03-29 | Stamm Luisa M | Chief Medical Officer | Grant | 23K | $0.00 | $0 | 41K |
| 2022-03-29 | Samar Michael P. | Chief Financial Officer | Grant | 26K | $0.00 | $0 | 79K |
| 2022-03-28 | Okazaki Jason A | Chief Operating Officer | Sell | 5K | $2.24 | $10K | 65K |
| 2021-08-09 | McHutchison John G | CEO and President | Sell | 12K | $3.60 | $44K | 126K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON3 Form 144 notices on file for ASMB worth $223K at the prices reported; 3 in the last 90 days worth $223K. Latest: Jason A. Okazaki filed on 2026-11-02 to sell 6,202 shares ($122K) from 2026-11-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-11-02 | Jason A. OkazakiOfficer, Director | 6K | $122K | 0.030% | 2026-11-02 | Morgan Stanley Smith Barney LLC |
| 2026-11-02 | Anuj GaggarOfficer | 3K | $51K | 0.013% | 2026-11-02 | Morgan Stanley Smith Barney LLC |
| 2026-11-02 | Nicole S. WhiteOfficer | 3K | $51K | 0.013% | 2026-11-02 | Morgan Stanley Smith Barney LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON23 holders report 5% or more of ASMB in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is GILEAD SCIENCES, INC. at 25.1% of the class (4,977,089 shares), filed 2026-05-27 for an event on 2026-05-22.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 1 | Paradigm BioCapital Advisors GP LLCother entity | 1.6M | 7.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Paradigm BioCapital Advisors LPpartnership | 1.6M | 7.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Senai Asefaw, M.D.individual | 1.6M | 7.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Paradigm BioCapital International Fund Ltd.corporation | 1.4M | 6.9% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | JANUS HENDERSON GROUP Ltd.parent holding company | 1.4M | 6.9% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Wehrly, Mark C.parent holding company, individual | 1.6M | 8.1% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Farallon Capital Management, L.L.C.investment adviser, other entity | 1.6M | 8.1% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Gehani, Varun N.parent holding company, individual | 1.6M | 8.1% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Giauque, Nicolasparent holding company, individual | 1.6M | 8.1% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Husen, Avner A.parent holding company, individual | 1.6M | 8.1% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Kim, David T.parent holding company, individual | 1.6M | 8.1% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Linn, Michael G.parent holding company, individual | 1.6M | 8.1% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Luo Patrick (Cheng)parent holding company, individual | 1.6M | 8.1% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Roberts, Jr., Thomas G.parent holding company, individual | 1.6M | 8.1% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Saito Edric C.parent holding company, individual | 1.6M | 8.1% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Short Daniel S.parent holding company, individual | 1.6M | 8.1% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Spokes, Andrew J. M.parent holding company, individual | 1.6M | 8.1% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Warren, John R.parent holding company, individual | 1.6M | 8.1% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Dapice Joshua J.parent holding company, individual | 1.6M | 8.1% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Dreyfuss, Philip D.parent holding company, individual | 1.6M | 8.1% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Dunn Hannah E.parent holding company, individual | 1.6M | 8.1% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Farallon Capital Institutional Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Farallon Capital Institutional Partners II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Farallon Capital Institutional Partners III, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Four Crossings Institutional Partners V, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Farallon Capital Offshore Investors II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Farallon Capital (AM) Investors, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Farallon Capital F5 Master I, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Farallon Partners, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Farallon Institutional (GP) V, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Farallon F5 (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-04 | 13G/Ano. 2 | Farallon Capital Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-05-27 | 13D/Ano. 4 | GILEAD SCIENCES, INC.corporation | 5.0M | 25.1% | 2026-05-22 |
| 2026-02-09 | 13G/Ano. 1 | Patel, Rajiv A.individual | 0 | 0.0% | 2025-12-31 |
| 2026-02-09 | 13G/Ano. 1 | Seybold, Williamindividual | 0 | 0.0% | 2025-12-31 |
| 2026-02-09 | 13G/Ano. 1 | Fried, Richard Bindividual | 0 | 0.0% | 2025-12-31 |
| 2025-12-08 | 13G | JANUS HENDERSON GROUP PLCinvestment adviser, parent holding company | 1.3M | 8.2% | 2025-11-28 |
13F holders
Tracked managers holding ASMB at their latest 13F. JSON5 of the 30 tracked managers held ASMB at their latest 13F, $25.1M in total at quarter-end prices. Point72 Asset Management is the largest at $12.7M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 461K | $12.7M | 0.01% | +116K |
| Millennium Management | 2026-06-30 | 299K | $8.2M | 0.00% | +65K |
| Citadel Advisors | 2026-06-30 | 96K | $2.6M | 0.00% | +70K |
| Renaissance Technologies | 2026-06-30 | 39K | $1.1M | 0.00% | +24K |
| Two Sigma Investments | 2026-06-30 | 18K | $491K | 0.00% | -3K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Assembly Biosciences in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Assembly Biosciences (ASMB), SEC CIK 1426800, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-08-31.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-11-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-14.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-06-17.JSON and CSV
- Company record
- EDGAR filing index for CIK 1426800Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of ASMB is sold short?
2,913,451 shares were held short at the 2026-10-15 settlement, 11.1 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ASMB's daily short volume?
On 2026-11-02, 57,576 of the 82,830 ASMB shares reported to FINRA were sold short, 69.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ASMB have fails to deliver?
The SEC's latest file shows 2,727 ASMB shares failed to deliver at settlement 2026-08-31. Fails are reported per settlement date and published twice a month with a lag.
Are ASMB insiders buying or selling?
No open-market insider trades were reported for ASMB in the last 90 days. The most recent filings are listed below. Latest filing: Bjorkquist Jeanette M (PFO and PAO) on 2026-06-17.
Have ASMB insiders filed to sell?
3 Form 144 notices on file for ASMB worth $223K at the prices reported; 3 in the last 90 days worth $223K. Latest: Jason A. Okazaki filed on 2026-11-02 to sell 6,202 shares ($122K) from 2026-11-02.
Who owns 5% or more of ASMB?
23 holders report 5% or more of ASMB in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is GILEAD SCIENCES, INC. at 25.1% of the class (4,977,089 shares), filed 2026-05-27 for an event on 2026-05-22.
Which tracked 13F managers own ASMB?
5 of the 30 tracked 13F managers held ASMB shares at their latest filing, $25.1M in all. The largest: Steve Cohen's Point72 Asset Management (461K shares, $12.7M), Izzy Englander's Millennium Management (299K shares, $8.2M), Ken Griffin's Citadel Advisors (96K shares, $2.6M), Renaissance Technologies (39K shares, $1.1M), Two Sigma Investments (18K shares, $491K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.